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OBJECTIVES: Clinical trials have shown that ranibizumab is efficacious in 
improving vision among patients with AMD. The objectives of this study are to: 
1) evaluate whether as needed (PRN) is as effective as monthly treatment; and 
2)compare the efficacy of ranibizumab 0.5mg treatment with: a)control; 
b)ranibizumab 0.3mg; and c)bevacizumab. METHODS: This is a systematic meta-
analysis review of 8 randomized controlled clinical phase III or IV trials with a 
minimum of one year follow-up that investigated the efficacy of ranibizumab in 
treating AMD. The dependent variables were effect sizes of visual acuity gained 
and odds ratios of percentage of patients who gained ≥15 visual acuity letters. 
Weighted multiple regression analyses were used to compare the monthly 
versus PRN treatment. RESULTS: Regression results showed no significant 
differences in efficacy between PRN and monthly treatment. The ranibizumab to 
control (placebo injection/surgery) comparison (4 effect sizes, 4 odds ratios, 
N=1047): showed that ranibizumab had significantly higher improvement in 
visual acuity (g=1.20, z=7.83, p<0.05) and a higher proportion of patients who 
gained ≥15 letters (OR: 6.37; 95% CI 3.96-9.98; p<0.05). When comparing 
ranibizumab dose (6 effect sizes, 5 odds ratios, N=3449): ranibizumab 0.5mg 
showed significantly higher improvement in letters gained (g=0.08, z=2.34, 
p<0.05) than ranibizumab 0.3mg. However, the proportion of patients who gained 
≥15 letters was not significantly different. The ranibizumab to bevacizumab 
comparison (3 effect sizes, 3 odds ratios, N= 800) revealed no significant 
differences. CONCLUSIONS: Ranibizumab 0.5mg was found to be more effective 
than control and ranibizumab 0.3mg. Monthly treatment was not significantly 
different from PRN. More clinical trials are needed to compare the efficacy of 
ranibizumab and bevacizumab.  
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THE BURDEN OF GLAUCOMA AND ITS COMPLICATIONS: A LARGE 
POPULATION-BASED COHORT STUDY  
Levkovitch-Verbin H, Goldshtein I, Chodick G, Zigman N, Shalev V 
Maccabi Healthcare Services, Tel Aviv, Israel  
OBJECTIVES: To investigate the burden and epidemiology of glaucoma in a large 
health maintenance organization (HMO) in Israel. METHODS: A retrospective 
cohort study, conducted using the electronic medical databases of Maccabi 
Healthcare Services (MHS), a 2 million member HMO in Israel. The study 
population consisted of all patients who were newly diagnosed with glaucoma 
between 2003 and 2010 at MHS. In addition, for prevalence calculation we 
included all patients who are currently (2012) active members of MHS. Collected 
data included personal characteristic, relevant surgical procedures, anti-
glaucoma medications, caregiver characteristics, comorbidity, possible 
complications (asthma, depression, cardiovascular diseases, cataract) and all-
cause mortality. We investigated the age- and sex-specific prevalence and 
incidence rates, and compared the medical comorbidity and mortality of 
glaucoma patients to the general HMO population. RESULTS: A total of 26,196 
prevalent glaucoma patients aged 40 or above were identified among active 
members of MHS in 2012 with an average prevalence of 35 per 1000. Prevalence 
was strongly associated with increasing age, ranging from 7 cases per 1000 at age 
45-50 to 212 per 1000 at age 85+. The 4 main prevalent pathologies among MHS 
population aged 40 or above were open angle glaucoma, pre or borderline 
glaucoma, unspecified glaucoma, and pseudo exfoliation with prevalence rates 
of 2%, 1.4%, 0.9% and 0.2%, respectively. A total of 11,512 incident glaucoma 
patients, who were diagnosed between 2003 and 2010 were identified, with an 
average incidence of 2.5 per 1000 among 40+ year old members. Overall, 1.5% of 
the study patients have undergone glaucoma surgery, 3% were blind and 41% 
were diagnosed with cataract. CONCLUSIONS: The current study demonstrates 
the potential use of automated medical databases to estimate the burden of 
glaucoma and its complications. The increased comorbidity and mortality 
among these patients has important implication for health authorities for 
prevention and delivery of health-care services.  
 
PSS4  
PREVALENCE AND INCIDENCE OF PATHOLOGIC MYOPIA AND RETINAL 
NEOVASCULARIZATION IN A US MANAGED CARE DATABASE  
Fortuny J1, Leteneux-Pantias C2, Xu X3, Plana E4 
1Novartis Farmaceutica S.A, Barcelona, Spain, 2Novartis Pharma AG, Basel, Switzerland, 3Beijing 
Novartis Pharma Co. Ltd., Shanghai, China, 4Novartis Farmacéutica S.A., Barcelona, Spain  
OBJECTIVES: The epidemiology of pathologic myopia (PM), an important cause of 
visual impairment worldwide, is poorly understood. This study analyzed data 
from a large US claims database to estimate the prevalence and incidence of PM 
and PM + retinal neovascularization (RNV). METHODS: Data were drawn from 
the MarketScan® Commercial Claims and Encounters database and Medicare 
Supplemental and Coordination of Benefits in the USA. ICD9 diagnostic codes for 
PM (360.21) and both PM + RNV (362.16) were used to identify cases; use of the 
diagnostic code on at least one occasion was required. A 1-year disease-free 
period was required for a diagnosis to be considered an incident case. RESULTS: 
MarketScan covered 45,226,794 patients in 2011; 43,581 and 1,781prevalent cases 
of PM and PM + RNV were identified, representing a prevalence of 9.64 (95% CI: 
9.55–9.73) and 0.39 (95% CI: 0.38–0.41) per 10,000 population, respectively. 
Incidence per 10,000 persons in 2011 was 2.75 (95% CI: 2.70–2.80) for PM and 0.09 
(95% CI: 0.08–0.10) for PM + RNV. Subjects with incident PM had a mean age of 
47.9±18.5 years, 46.5% were under 50 years old, and 62.3% were females, whereas 
subjects with PM + RNV had a mean age of 55.1±14.5, 30.3% were younger than 
50 years old, and 71.1% were females. CONCLUSIONS: Prevalence and incidence 
estimates of PM among the commercially insured US population in 2011 were 
approximately 9.6 and 2.7 per 10,000 persons, respectively. PM+RNV represents 
approximately 3−4% of patients with PM. Using only one diagnostic code to 
identify cases may overestimate prevalence and incidence as there is potential 
to include some diagnoses that would later be ruled out as true cases. Both PM 
and PM+RNV are often diagnosed in individuals younger than 50 years of age and 
the majority of patients are female.  
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BUDGETARY IMPACT OF INTRAVITREAL AFLIBERCEPT INJECTION (IAI) IN 
TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A US 
HEALTH PLAN OF ADULTS AGES 65 YEARS AND OLDER  
Vitti R1, Clements KM2, Panchmatia H3, Hulbert E4, Wittrup-Jensen K5, Lewis BE1 
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 2OptumInsight, Medford, MA, USA, 
3OptumInsight, Cambridge, MA, USA, 4OptumInsight, Eden Prairie, MN, USA, 5Bayer Schering 
Pharma, Berlin, Germany  
OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly 
improves visual acuity over time in patients with neovascular (“wet”) age-related 
macular degeneration (wAMD). In two identical phase 3 trials, IAI dosed 2mg 
every 2 months, following 3 initial monthly doses (2Q8) demonstrated clinically 
equivalent efficacy and a similar safety profile to RBZ 0.5mg dosed monthly 
(RQ4). We assessed the budgetary impact of adding IAI 2Q8 to a formulary of a 
hypothetical one million member US health plan. METHODS: A Markov model 
characterized treatment with IAI 2Q8 and RQ4 over time. Health states were 
based on visual acuity in the better-seeing eye. Efficacy and cost estimates came 
from clinical trial data and published literature. The model calculated direct 
medical costs, including costs of drug, administration, monitoring, visual 
impairment, and adverse events. Ten percent of patients were assumed to be 
treated in both eyes. We calculated budgetary impact by comparing estimated 
costs over three years from current (100% RBZ market share) through future 
scenarios (IAI market share: Year 1, 22%; Year 2, 42%; Year 3, 51%). Model 
outcomes include total costs over three years in current and future scenarios, 
net costs, and cost per-member per-month (PMPM). RESULTS: In a one million 
member plan, 2,800 were newly treated for wAMD. Total budget was $79.2 
million in Year 1, $147.9 million in Year 2 and $152.4 million in Year 3 in the 
current scenario, and $71.9 million, $126.5, and $121.2 million in Years 1, 2 and 3 
in the future scenario. Net budget impact ranged from $-7.3 million in Year 1 to 
$-31.2 million in Year 3, or $0.61, $1.78, and $2.60 PMPM savings in Years 1, 2, and 
3. CONCLUSIONS: Adding IAI 2Q8 to a US formulary saves money in the first 
three years, primarily due to reduced injection frequency compared to RQ4.  
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COST ANALYSIS OF PARS PLANA VITRECTOMY FOR THE TREATMENT OF 
SYMPTOMATIC VITREOMACULAR ADHESION: A BOTTOM-UP COSTING 
PERSPECTIVE  
Nicod E1, Jackson T2, Grimaccia F1, Angelis A1, Kanavos P1 
1London School of Economics and Political Science, London, UK, 2King’s College Hospital, London, 
UK  
The direct cost to the NHS of pars plana vitrectomy (PPV) is unknown since a 
bottom-up costing exercise has not been undertaken. Health care resource group 
(HRG) costing relies on a top-down approach. OBJECTIVES: To quantify the direct 
cost of PPV for vitreomacular traction (VMT), epiretinal membrane (ERM) and 
macular hole (MH). METHODS: Each of five NHS vitreoretinal units recorded the 
indication for surgery and all procedure elements for a minimum of 30 
consecutive PPVs, to include at least 10 cases of VMT, ERM, or MH. In-surgery 
bottom-up costing was undertaken by prospectively recording all consumables, 
equipment and staff salaries associated with surgery, between March and 
September 2012. Out-of-surgery costs, namely before and after surgery between 
admission and discharge, were estimated based on accounting costs recorded in 
one site. RESULTS: Of 151 PPVs, 57 were for MH (16.6%), ERM (15.2%), or VMT 
(4%). The average surgical time was 1.22 hours [range 0.96-1.38], corresponding to 
an average staff cost of £280.40 [£184.90-£376.70]. The average cost of 
consumables was £534.60 [£406.55-£688.85], and of equipment £87.75 [£28.10-
£139.15]. The average direct cost of PPV in theatre was £901.10 [£671.00-£1185.55]. 
Average out-of-surgery costs were estimated at £325.35, including nursing staff, 
extra consumables and hospitalisation costs. This resulted in a total cost of 
£1673.80 [£1496.40-£1863.30], including 30% overheads. This cost estimate is 
considered an under-estimate because of lack of available data on departmental-
level general costs, medical and anaesthetic staff costs incurred out-of-surgery. 
The average effective HRG tariff reimbursed was £1701.20. CONCLUSIONS: These 
figures indicate that the real cost incurred is likely to be higher than the 
reimbursed tariff, but it may be cost-effective for NHS hospitals to undertake 
additional PPVs for VMT, ERM and MH, if they can amortise existing 
infrastructure with a sufficient number of interventions to benefit from 
economies of scale.  
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THE COST AND THE EDUCATIONAL IMPACT OF COCHLEAR IMPLANTATION IN 
CHILDREN OVER A FOUR YEAR PERIOD IN FRANCE  
Costa N1, Lejalé L2, Bongard V1, Deguine O3, Fraysse B3, Molinier L3 
1INSERM, Toulouse, France, 2Toulouse school of economics, Toulouse, France, 3University Hospital 
of Toulouse, Toulouse, France  
OBJECTIVES: Cochlear implants (CI) are electronic devices introduced surgically 
into the inner ear. This is the only medical treatment for profound total 
deafness. CI is particularly useful in children because they can have an impact 
on the children education. The aim of this study is to assess the cost and the 
educational impact of CI in French implanted children over a four year period 
METHODS: 268 profoundly deaf children were recruited and implanted between 
September 2002 and December 2004 in 16 specialized French hospitals. The 
educational impact was assessed in children aged less than 2 years and aged 
over 2 years using the educational rate evolution and the type of integrated 
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school 4 years after implantation. This prospective economic analysis adopted 
the health care payer’s perspective and took into account direct medical,  
direct non-medical and indirect costs RESULTS: Two hundred and three 
implanted children were included in the study and followed during four years. 
The rate of school children implanted later (i.e. after 2 years) goes from 71,4% to 
95,3% four year after implantation and goes from 28,6% to 87,5% for children 
implanted earlier (i.e. before 2 years). If children are implanted earlier (i.e. < 2 
years), they are more likely to integrate ordinary classroom four years after 
implantation (69.0%) than if children were implanted later (46,9%). The mean 
total costs over one year period were €34,703 (+/- 5,231). The preoperative, 
implantation and one year follow-up mean costs were €1,304 (+/- 1,014), €24,285 
(+/- 1,150) and €9,115 (+/-4,694) respectively. Ambulatory care was the costs 
driver in preoperative and one year follow up costs (42,0% and 66,6% 
respectively), while in implantation costs the driver was implant cost (90,0%). 
The cost of the next three year follow-up is being processed CONCLUSIONS: CI is 
an expensive medical treatment but they have a positive impact on children 
education.  
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USE OF BIOLOGIC AGENTS IN THE TREATMENT OF PSORIASIS: AN ANALYSIS 
OF THE QUEBEC PROVINCIAL DRUG REIMBURSEMENT PROGRAM  
DATABASE  
Lachaine J1, Beauchemin C1, Desjardins O2 
1University of Montreal, Montreal, QC, Canada, 2Abbvie, St-Laurent, QC, Canada  
OBJECTIVES: The purpose of this study was to describe the use of biologics in the 
treatment of psoriasis, in a real life Canadian setting. METHODS: A retrospective 
study of the Quebec provincial drug reimbursement program (RAMQ) was 
conducted using a random sample of patients who had received at least one 
diagnosis of psoriasis (ICD-9: 6961/6968/6969) and had used at least one biologic 
in the period from January 1, 2001 to August 31, 2011. Agents included in the 
study were adalimumab, etanercept, infliximab, abatacept, anakinra, efalizumab, 
golimumab, rituximab, tocilizumab and ustekinumab. The use of biologics was 
analyzed in terms of patient characteristics, treatment patterns and health care 
resource utilization. RESULTS: A total of 1382 patients who used at least one 
biologic were included in the study. The average age was 45,8 years (SD=15,0) 
and the proportion of men was slightly higher (53,5%). Most patients had other 
concomitant inflammatory diseases (80,8%), such as rheumatoid arthritis (48.6%), 
psoriatic arthritis (44.9%), and Crohn’s disease (15.0%). During the course of the 
study period, most patients used only one biologic (80.3%). Out of the 34,320 
scripts for a biologic, 16,421 were for etanercept (47.9%), 8,868 for adalimumab 
(25.8%) and 7174 for infliximab (20.9%). Average annual cost for biologics in 
psoriasis was $19,026 and was slightly higher in the first year of treatment. Costs 
per patient of health care resource utilization in the year following the initiation 
of a biologic were $CAD486 lower than during the one year period preceding the 
biologic initiation; 45% of this reduction was associated with outpatient visits 
and 23% with hospitalizations. CONCLUSIONS: Psoriasis is associated with many 
other inflammatory conditions. Biologics use for the treatment of psoriasis has 
significantly increased over time. Although this is associated with higher 
medication costs, the initiation of a biologic is associated with a reduction of 
other medical costs.  
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DIALYSIS FACILITY-LEVEL ANALYSIS OF THE ECONOMIC IMPACT OF PRURITUS 
AMONG END-STAGE RENAL DISEASE PATIENTS RECEIVING HEMODIALYSIS 
THERAPY  
Ramakrishnan K1, Graybill CA1, Massey K2, Sood V2, Sibbel SP1 
1DaVita Clinical Research, Minneapolis, MN, USA, 2Mitsubishi Tanabe Pharma America, Inc., 
Warren, NJ, USA  
OBJECTIVES: Itchy and dry skin, symptoms of pruritus, are commonly reported 
by patients with end-stage renal disease (ESRD) and may impact health 
outcomes. However, the economic burden to dialysis facilities is poorly 
understood. This retrospective cohort study measured dialysis-related costs in 
patients reporting itchiness/dryness at a large dialysis organization (LDO). 
METHODS: Adult patients (≥ 18 years old) were identified in the LDO database if 
they responded to the Kidney Disease Quality of Life (KDQOL) survey 
administered between December 1, 2008 and June 30, 2012, which included 
questions about itchy/dry skin. Medicare patients were included if they 
answered a survey ≥ 3 months after dialysis initiation. Costs of medications, 
laboratories, and missed sessions were measured over a 6-month follow-up 
period. Patients were censored for death, transplant, change in treatment 
modality, discontinued treatment, or loss of observation. Mean utilization for 
medication and laboratory costs was determined by unit prices published in RED 
BOOK and physician fee and coding guide. Costs of missed sessions were derived 
by the standard 2012 Medicare composite reimbursement rate for in-center 
dialysis. Cost differences were determined by covariate adjusted generalized 
linear mixed models. RESULTS: Over the 6-month period, in unadjusted models 
(n = 38,815) increasing trends in total costs were observed with increasing 
severity of itchiness ($507, $803, $1,520, and $2,238) and dryness ($542, $840 
$1,610, and $2,729) compared to no itchiness/dryness. The adjusted model 
demonstrated similar trends, yet attenuated differences. A subgroup analysis 
comparing combined severe itchiness and dryness versus neither itchiness nor 
dryness showed a mean estimate of $2348 increased costs. All results were 
statistically significant (p < 0.0001). Drivers of overall dialysis costs were 
increased utilization of erythropoiesis-stimulating agents and missed sessions. 
CONCLUSIONS: ESRD patients with pruritus symptoms impose higher costs to 
dialysis facilities. Pruritus symptom relief may be an important target for 
therapeutic intervention.  
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COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT INJECTION (IAI) IN 
TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE US  
Vitti R1, Clements KM2, Panchmatia H3, Hulbert E4, Wittrup-Jensen K5, Lewis BE1 
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 2OptumInsight, Medford, MA, USA, 
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OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly improves 
visual acuity over time in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In two identical phase 3 trials, IAI dosed every 2 months, 
following 3 initial monthly doses demonstrated clinically equivalent efficacy and a 
similar safety profile to RBZ0.5mg dosed monthly (RBZQ4). We assessed U.S. cost 
effectiveness of IAI 2Q8 compared with RBZ Q4 in treating wAMD. METHODS: A 
Markov model was developed to characterize treatment with IAI 2Q8 and RBZ Q4 
over two years. Patients move among health states based on visual acuity in the 
better-seeing eye. The model assumed patients discontinue treatment when vision 
drops below 20/400; ten percent were assumed to be treated in both eyes. The 
model calculated direct medical costs (drug, administration, monitoring, vision 
impairment and adverse events) and quality adjusted life-years (QALYs). Model 
parameters were estimated from clinical trial data, published literature, or expert 
opinion. Cost-effectiveness was reported through incremental cost-effectiveness 
ratios (ICERs) for a 2-year horizon. Costs and outcomes were discounted 3% per 
year. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: 
Treatment with IAI 2Q8 cost $30,700 over two years, compared with $54,300 for RBZ 
Q4. Treatment cost was the largest cost component, comprising 78% and 85% of 
total costs of the IAI and RBZ regimens, respectively. Both regimens resulted in 
similar QALY gains (1.124 for IAI, 1.125 for RBZ). Compared with IAI, RBZ cost nearly 
$26 million per QALY gained. The model was most sensitive to unit drug cost and 
utility weights. IAI was dominant in 41% of PSA iterations. CONCLUSIONS: In 
treating wAMD, IAI 2mg dosed every 2 months, following 3 initial monthly doses is 
less expensive than monthly RBZ. Both demonstrate similar efficacy. Of the two, IAI 
is the cost-effective alternative at conventional willingness to pay thresholds.  
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THE COST-EFFECTIVENESS OF THREE COMMERCIALLY AVAILABLE CELLULAR 
ENGINEERED SKIN SUBSTITUTES USED TO TREAT VENOUS LEG ULCERS  
Carter M1, Waycaster C2, Schaum K3 
1Strategic Solutions Inc, Cody, WY, USA, 2Healthpoint Ltd., Fort Worth, TX, USA, 3Healthpoint 
Biotherapeutics, Fort Worth, TX, USA  
OBJECTIVES: To determine the comparative cost-effectiveness of three 
commercially available cellular engineered skin substitutes used in the 
treatment of venous leg ulcers (VLU). METHODS: A Markov simulation model 
was developed to compare the one year direct costs and outcomes of a porcine 
small intestinal submucosa (SIS) wound matrix to fibroblast-derived (FSS) and 
fibroblast/keratinocyte-derived (FKSS) cellular and/or tissue-derived products 
(CTDP) used in the treatment of chronic VLUs. The model used three health 
states: a chronic ulcer, a healed ulcer and death. To predict clinical and 
economic outcomes a systematic literature search was conducted to identify 1) 
comparative chronic VLU clinical trials that reported healing/recurrence 
outcomes for the three skin substitutes, and 2) economic studies reporting VLU 
treatments and resource utilization. The effectiveness of the products was 
assumed equal to that reported in four clinical trials identified in the literature. 
Ulcer-free weeks were used as the measure of clinical effectiveness. Direct costs 
of treatment were derived from Medicare-allowable costs and economic studies 
identified in the literature which included costs associated with hospitalization, 
home health care, ambulatory clinic visits, CTDP products, drugs, compression 
stockings and other resources associated with VLU care. The payer perspective 
was taken in the analysis and sensitivity analyses were performed to assess 
model uncertainty. RESULTS: SIS was the economically dominant therapy 
compared to FKSS and FSS with a comparative effectiveness ratio of $215 per 
ulcer-free week versus $367 and $409, respectively. Relative to SIS, the 
incremental cost-effectiveness ratio (ICER) for FKSS was $1609 while the ICER for 
FSS was $1132. SIS remained the least costly alternative per ulcer-free week 
across all sensitivity analyses. CONCLUSIONS: When cellular and/or tissue-
derived products are needed for chronic VLU therapy our results indicate that SIS 
is the most cost-effective choice between the three commercially available 
alternatives analyzed.  
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COST-EFFECTIVENESS OF DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 
TREATMENT OF MACULAR EDEMA (ME) FOLLOWING CENTRAL RETINAL VEIN 
OCCLUSION (CRVO)  
Vicente C1, Koster B2, Zilbershtein R1, Piwko C1 
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OBJECTIVES: This pharmacoeconomic study evaluates the cost-effectiveness of 
OZURDEX™ (dexamethasone intravitreal implant) compared to observation 
(primary intervention at the time of model development) in management of 
patients with ME following CRVO, from a Canadian public payer and societal 
perspective. METHODS: A Markov model was developed to estimate lifetime 
outcomes and costs for patients with ME and vision loss following CRVO, 
receiving either OZURDEXTM implant or observation. The model consists of six 
heath states based on Best Corrected Visual Acuity (BCVA) and one absorbing 
(Death) state. The model was developed using GENEVA trial results with a 
systematic review for extrapolation of clinical data beyond the trial period. The 
model incorporated direct medical costs of managing patients with CRVO, 
treatment, drug related adverse events and vision loss; a societal perspective 
was examined as well. Utilities were derived from the published literature based 
